Lupin: Receives U.s. FDA Approval For Diazepam Injection Usp

 31 Jul 2026 05:24 PM

Lupin: Receives U.s. FDA Approval For Diazepam Injection Usp

Lupin: Co. Gets U.S. FDA Approval For Sugammadex Injection, Similar To Merck's Bridion Injection, For Reversing Neuromuscular Blockade During Surgery.

 31 Jul 2026 11:15 AM

Lupin: Co. Gets U.S. FDA Approval For Sugammadex Injection, Similar To Merck's Bridion Injection, For Reversing Neuromuscular Blockade During Surgery.

Lupin: Company Receives U.S. FDA Approval And Launches Sugammadex Injection

 30 Jul 2026 10:13 PM

Lupin: Company Receives U.S. FDA Approval And Launches Sugammadex Injection

Lupin: Company Gets Approval For Diazepam Injection In The U.S.

 28 Jul 2026 09:02 PM

Lupin: Company Gets Approval For Diazepam Injection In The U.S.

Lupin: Company To Hold Q1 Earnings Call On August 7 At 4:30 PM

 22 Jul 2026 10:17 PM

Lupin: Company To Hold Q1 Earnings Call On August 7 At 4:30 PM

Lupin: Company To Review Q1 Results On August 6

 22 Jul 2026 04:38 PM

Lupin: Company To Review Q1 Results On August 6

Lupin: Company Grants Kaveri Therapeutics Exclusive License For Oncology Program And Acquires 82.2% Equity Stake For $1.6 Million.

 21 Jul 2026 08:36 AM

Lupin: Company Grants Kaveri Therapeutics Exclusive License For Oncology Program And Acquires 82.2% Equity Stake For $1.6 Million.

Lupin: Company Gets EIR From U.S. FDA For Somerset Facility With VAI Status

 02 Jul 2026 07:51 AM

Lupin: Company Gets EIR From U.S. FDA For Somerset Facility With VAI Status

Lupin: Netherlands Unit Nanomi Increases Share In Multicare Philippines To 99.89%

 01 Jul 2026 06:25 PM

Lupin: Netherlands Unit Nanomi Increases Share In Multicare Philippines To 99.89%

Lupin: Gets EMA Nod To Expand Namuscla® For Kids With New 62 Mg & 83 Mg Options

 01 Jul 2026 04:49 PM

Lupin: Gets EMA Nod To Expand Namuscla® For Kids With New 62 Mg & 83 Mg Options

Lupin: Company Gets Tentative Approval From U.S. FDA For Enzalutamide Tablets

 26 Jun 2026 10:14 AM

Lupin: Company Gets Tentative Approval From U.S. FDA For Enzalutamide Tablets

Lupin: Company Introduces Azilsartan Medoxomil Tablets In The U.S.

 17 Jun 2026 05:11 PM

Lupin: Company Introduces Azilsartan Medoxomil Tablets In The U.S.

Lupin: Partners With Laboratorios ERN To Introduce Luforbec® In Spain Aimed At Treating Adult Asthma And COPD, Enhancing Access To Quality Respiratory Care.

 08 Jun 2026 12:14 PM

Lupin: Partners With Laboratorios ERN To Introduce Luforbec® In Spain Aimed At Treating Adult Asthma And COPD, Enhancing Access To Quality Respiratory Care.

Lupin Limited: Company and Natco Get FDA Approval for Eribulin Mesylate Injection, Used for Metastatic Breast Cancer and Liposarcoma; Expected Yearly Sales of $43.7 Million in the U.S.

 03 Jun 2026 11:02 AM

Lupin Limited: Company and Natco Get FDA Approval for Eribulin Mesylate Injection, Used for Metastatic Breast Cancer and Liposarcoma; Expected Yearly Sales of $43.7 Million in the U.S.

Lupin: CFO Swaminathan Says Co. Aiming for Big Specialty Deals While Keeping Debt and Risk in Check. - MC

 01 Jun 2026 11:07 AM

Lupin: CFO Swaminathan Says Co. Aiming for Big Specialty Deals While Keeping Debt and Risk in Check. - MC

Lupin: Company Gets Approval in China for Oseltamivir Phosphate Oral Suspension.

 22 May 2026 03:51 PM

Lupin: Company Gets Approval in China for Oseltamivir Phosphate Oral Suspension.

Lupin: Company Gets Tentative Approval From US FDA For Refevenacin Inhalation Solution.

 18 May 2026 09:16 PM

Lupin: Company Gets Tentative Approval From US FDA For Refevenacin Inhalation Solution.

Lupin: Inaugurates Atharv Ability, an Advanced Multidisciplinary Neuro-Rehabilitation Center in Delhi.

 15 May 2026 11:12 AM

Lupin: Inaugurates Atharv Ability, an Advanced Multidisciplinary Neuro-Rehabilitation Center in Delhi.

Lupin Limited: Gets U.S. FDA Green Light For Famotidine Injection Approval.

 13 May 2026 06:31 PM

Lupin Limited: Gets U.S. FDA Green Light For Famotidine Injection Approval.

Lupin: Projects Effective Tax Rate For FY27 At 25% To 26% Because Of Reduced Incentives. US Revenue Expected To Exceed $1 Billion For FY27 Even With Some Competition-Related Decline. New Products And Business Growth May Help Mitigate Losses.

 11 May 2026 08:56 AM

Lupin: Projects Effective Tax Rate For FY27 At 25% To 26% Because Of Reduced Incentives. US Revenue Expected To Exceed $1 Billion For FY27 Even With Some Competition-Related Decline. New Products And Business Growth May Help Mitigate Losses.